Merck Serono’s US affiliate EMD Serono has signed a research agreement with Pfizer and the Broad Institute focussing on the genomic profiling of patients with the autoimmune disorder Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN; kidney inflammation).
The project, which will be jointly funded by Merck Serono and Pfizer, aims to identify biomarkers to better define target patient populations for future therapies.
As such, under the collaboration the Broad Institute will investigate clinical samples obtained from SLE and LN patients, applying biochemical and next-generation sequencing technologies.
The drugmakers, as sponsoring members, will receive real-time access to all data and analysis.
“Combined with the Broad Institute’s technical know-how, we see this collaboration aiming for a significant contribution to potential future innovative treatments of Lupus and Lupus Nephritis,” said Harsukh Parmar, Head of the Translational Innovation Platform Immunology & Neurodegenerative Diseases at Merck Serono.
This article has been extracted from http://www.pharmatimes.com/Article/14-04-02/Merck_Serono_ties_up_with_Pfizer_and_Broad_Institute.aspx#ixzz2xjwDkiUB
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.
For more information please visit www.montash.com